The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets

Obesity

Volumn 17, Issue 10, 2009, Pages 1856-1860

  Getty Kaushik, Lisa ^a   Richard, Ann Marie T ^a   Deeney, Jude T ^a   Krawczyk, Sarah ^a   Shirihai, Orian ^a   Corkey, Barbara E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; GLUCOSE; INSULIN; PALMITIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; MALE; METABOLISM; OBESITY; PANCREAS ISLET; PATHOPHYSIOLOGY; RAT; SECRETION; ZUCKER RAT;

ANIMALS; GLUCOSE; INSULIN; ISLETS OF LANGERHANS; MALE; OBESITY; PALMITATES; PIPERIDINES; PYRAZOLES; RATS; RATS, ZUCKER; RECEPTOR, CANNABINOID, CB1; SECRETORY RATE;

ANIMALIA; RATTUS;

EID: 70349515011     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.234     Document Type: Article

References (37)

1. Cota D, Marsicano G, Tschöp M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431.
2. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-589.
3. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100.
4. Proulx K, Cota D, Castañeda TR et al. Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. Am J Physiol Regul Integr Comp Physiol 2005;289:R729-R737.
5. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008;51:1356-1367.
6. Di Marzo V, Goparaju SK, Wang L et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825.
7. Blüher M, Engeli S, Klöting N et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55:3053-3060.
8. Côté M, Matias I, Lemieux I et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31:692-699.
9. Pagano C, Pilon C, Calcagno A et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;92:4810-4819.
10. Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
11. Matias I, Vergoni AV, Petrosino S et al. Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology 2008;54:206-212.
12. Kola B, Hubina E, Tucci SA et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005;280:25196-25201.
13. Lichtman AH, Cravatt BF. Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005;115:1130-1133.
14. Ravinet-Trillou C, Arnone M, Delgorge C et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-R353.
15. Ravinet-Trillou C, Delgorge C, Menet C, Arnone M, Soubrié P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28:640-648.
16. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999;143:315-317.
17. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3-10.
18. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999;42:128-138.
19. Gómez R, Navarro M, Ferrer B et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612-9617.
20. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003;462:125-132.
21. Nissen SE, Nicholls SJ, Wolski K et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-1560.
22. Wright SM, Dikkers C, Aronne LJ. Rimonabant: new data and emerging experience. Curr Atheroscler Rep 2008;10:71-78.
23. Jbilo O, Ravinet-Trillou C, Arnone M et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567-1569.
24. Juan-Picó P, Fuentes E, Bermúdez-Silva FJ et al. Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell. Cell Calcium 2006;39:155-162.
25. Bermúdez-Silva FJ, Suárez J, Baixeras E et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008;51:476-487.
26. Matias I, Cristino L, Di Marzo V. Endocannabinoids: some like it fat (and sweet too). J Neuroendocrinol 2008;20 Suppl 1:100-109.
27. Starowicz KM, Cristino L, Matias I et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008;16:553-565.
28. Bermudez-Silva FJ, Serrano A, Diaz-Molina FJ et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006;531:282-284.
29. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors. Regul Pept 2008;145:49-53.
30. Samols E, Stagner JI. Intra-islet regulation. Am J Med 1988;85:31-35.
31. Longo EA, Tornheim K, Deeney JT et al. Oscillations in cytosolic free Ca2+, oxygen consumption, and insulin secretion in glucose-stimulated rat pancreatic islets. J Biol Chem 1991;266:9314-9319.
32. Hirose H, Maruyama H, Kido K et al. α- and β-Cell function in obese Zucker (fa/fa) rats: a study with the isolated perfused pancreas. Clin Sci 1994;86:311-316.
33. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-870.
34. Després J P, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
35. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295: 761-775.
36. Van Gaal L F, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397. (Pubitemid 40523733)
37. Morens C, Sirot V, Scheurink AJ, van Dijk G. Low-carbohydrate diets affect energy balance and fuel homeostasis differentially in lean and obese rats. Am J Physiol Regul Integr Comp Physiol 2006;291: R1622-R1629.